Porton(SZ:300363) Zheng Quan Shi Bao Wang·2025-12-22 12:08Core Insights - Nona Bio and Boteng have established a deep strategic partnership focusing on the full lifecycle R&D and production of complex antibody therapies, addressing industry challenges such as high compliance requirements and long conversion cycles [1][3] Group 1: Company Overview - Nona Bio is an international innovative biotechnology company that provides integrated solutions for biopharmaceuticals from discovery to preclinical development, leveraging its Harbour Mice fully human antibody technology platform [2] - Boteng is a leading international CDMO with capabilities across small molecules, peptides, oligonucleotides, proteins, and gene therapies, operating 18 R&D centers and manufacturing bases globally [3] Group 2: Strategic Collaboration - The collaboration aims to combine Nona's R&D strengths in new modalities with Boteng's core capabilities in protein and conjugate drug platforms, creating a benchmark model of "Chinese innovation + global manufacturing" [5] - A joint development management team will be established to facilitate integrated development and comprehensive management of relevant projects, focusing on complex antibodies throughout their lifecycle [3][4] Group 3: Market Position and Future Outlook - The partnership signifies a significant step for both companies in the complex antibody field, aiming to enhance their comprehensive capabilities and accelerate the industrialization of complex antibodies and conjugate therapies [4][5] - Nona Bio's CEO emphasized the importance of this collaboration in transforming leading antibody discovery technologies into globally competitive clinical candidates and commercial products [4]